Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-6921fe94b12d3679a96f1d5a8683a92f"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-6921fe94b12d3679a96f1d5a8683a92f"/>
<resource>
<Composition>
<id value="composition-en-6921fe94b12d3679a96f1d5a8683a92f"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-6921fe94b12d3679a96f1d5a8683a92f"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-6921fe94b12d3679a96f1d5a8683a92f</b></p><a name="composition-en-6921fe94b12d3679a96f1d5a8683a92f"> </a><a name="hccomposition-en-6921fe94b12d3679a96f1d5a8683a92f"> </a><a name="composition-en-6921fe94b12d3679a96f1d5a8683a92f-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/857/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - voncento</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/857/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp6921fe94b12d3679a96f1d5a8683a92f"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - voncento"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Voncento is and what it is used for</li><li>What you need to know before you use Voncento</li><li>How to use Voncento</li><li>Possible side effects</li><li>How to store Voncento</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What voncento is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What voncento is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The product is made from human plasma (the liquid part of the blood) and contains the active substances called human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF). Voncento is used for all age groups to prevent or to halt bleeding caused by the lack of VWF in von Willebrand disease (VWD) and the lack of FVIII in haemophilia A. Voncento is only used when treatment with another medicine, desmopressin, is not effective alone or cannot be given. VWF and FVIII are involved in blood clotting. Lack of either factor means that blood does not clot as quickly as it should so there is an increased tendency to bleed. The replacement of VWF and FVIII by Voncento will temporarily repair the blood clotting mechanisms. As Voncento contains both FVIII and VWF, it is important to know which factor you most need. If you have haemophilia A your doctor will prescribe you Voncento with the number of units of FVIII specified. If you have VWD your doctor will prescribe you Voncento with the number of units of VWF specified.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take voncento"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take voncento"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Voncento</p><p>If you are allergic to VWF or FVIII or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Traceability It is strongly recommended that every time Voncento is given, you record the date of administration, the batch number and the injected volume in your treatment diary. Talk to your doctor, nurse or pharmacist before taking Voncento.</p><p>Allergic (hypersensitivity) reactions are possible. If symptoms of hypersensitivity occur, you should stop using the medicine immediately and contact your doctor. Your doctor should inform you of the early signs of hypersensitivity reactions. These include hives, generalised skin rash, tightness of the chest, wheezing, fall in blood pressure and anaphylaxis (a serious allergic reaction that causes severe difficulty in breathing, or dizziness).</p><p>The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all factor VIII medicines. These inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. If your or your child s bleeding is not being controlled with Voncento, tell your doctor immediately.</p><p>If you have been told you have heart disease or are at risk for heart disease, tell your doctor or pharmacist.</p><p>If for the administration of Voncento you will require a central venous access device (CVAD), the risk of CVAD-related complications including local infections, bacteria in the blood (bacteremia) and the formation of a blood clot in the blood vessel (thrombosis) where the catheter is inserted should be considered by your doctor.</p><p>von Willebrand disease If you have a known risk of developing blood clots, you must be monitored for early signs of thrombosis (blood clotting). Your doctor should give you treatment to prevent thrombosis. Virus safety When medicines are made from human blood or plasma, certain measures are put in place by the manufacturer to prevent infections being passed on to patients. These include:</p><p>careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,</p><p>the testing of each donation and pools of plasma for signs of virus/infections,</p><p>inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections. The measures taken are considered effective for so-called enveloped viruses such as human immunodeficiency virus (HIV, the AIDS virus), hepatitis B virus and hepatitis C virus (which cause inflammation of the liver), and for the non-enveloped hepatitis A virus (which also causes inflammation of the liver). The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious</p><p>for pregnant women (as there is a risk of infection of the unborn child) and</p><p>for individuals with a weakened immune system or with an increased production of red blood cells due to certain types of anaemia (e.g. sickle cell anaemia or haemolytic anaemia). Your doctor may recommend that you consider being vaccinated against hepatitis A and B if you regularly/repeatedly receive human plasma-derived medicines such as Voncento. Children and adolescents The listed warnings and precautions apply to children and adolescents. Other medicines and Voncento</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>During pregnancy and breast-feeding, Voncento should be given only if it is clearly needed. Driving and using machines Voncento does not affect your ability to drive and use machines. Voncento contains sodium The presentations 250 IU FVIII /600 IU VWF (5 ml solvent) and 500 IU FVIII /1200 IU VWF (5 ml solvent) contain up to 14.75 mg sodium per vial (main component of cooking/table salt). This is equivalent to 0.74 % of the recommended maximum daily dietary intake of sodium for an adult. The presentations 500 IU FVIII /1200 IU VWF (10 ml solvent) and 1000 IU FVIII /2400 IU VWF (ml solvent) contain up to 29.50 mg sodium per vial (main component of cooking/table salt). This is equivalent to 1.48% of the recommended maximum daily dietary intake of sodium for an adult.</p></div>
</text>
</section>
<section>
<title value="3. How to take voncento"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take voncento"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Your treatment should be monitored by a doctor who is experienced in the treatment of blood clotting disorders. If your doctor thinks you could administer Voncento yourself, appropriate instructions will be provided to you by your doctor. Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Dose The amount of VWF and FVIII you need to take and the duration of treatment depend on:</p><p>the severity of your disease</p><p>the site and intensity of the bleeding</p><p>your clinical condition</p><p>your body weight (see also section The following information is intended for healthcare professionals only ). If you have been prescribed Voncento to use at home, your doctor will make sure that you are shown how to inject it and how much to use. Follow the directions given to you by your doctor. Use in children and adolescents Dosing in children and adolescents aged < 18 years is based on body weight and is therefore generally based on the same instructions as for adults. In some cases, especially in younger patients, higher doses may be needed. If you use more Voncento than you should Five cases of overdose have been reported from clinical trials. No side effects have been associated with these reports. The risk of developing blood clots (thrombosis) cannot be excluded in case of an extremely high dose, especially in patients with VWD. If you forget to use Voncento</p><p>Proceed with your next dose immediately and continue at regular intervals as advised by your doctor.</p><p>Do not take a double dose to make up for a forgotten dose. If you stop using Voncento Do not stop using Voncento without consulting your doctor. Reconstitution and application General Instructions</p><p>The powder must be mixed with the solvent (liquid) and withdrawn from the vial under aseptic conditions.</p><p>Voncento must not be mixed with other medicines, diluents or solvents except those mentioned in section 6.<br/>The solution should be clear or slightly opalescent, i.e. it might be sparkling when held up to the light but must not contain any obvious particles. After filtering or withdrawal (see below) the solution should be checked by eye, before it is used. Do not use the solution if it is visibly cloudy or if it contains flakes or particles.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements and as instructed by your doctor. Reconstitution Without opening the vials, warm the Voncento powder and the liquid to room or body temperature. This can be done either by leaving the vials at room temperature for about an hour, or by holding them in your hands for a few minutes. DO NOT expose the vials to direct heat. The vials must not be heated above body temperature (37 C). Carefully remove the protective caps from the vials, and clean the exposed rubber stoppers with an alcohol swab. Allow the vials to dry before opening the Mix2Vial package (which contains the filter transfer device), then follow the instructions given below. 1</p><ol type="1"><li>Open the Mix2Vial package by peeling off the lid. Do not remove the Mix2Vial from the blister package! 2</li><li>Place the solvent vial on an even, clean surface and hold the vial tight. Take the Mix2Vial together with the blister package and push the spike of the blue adapter end straight down through the solvent vial stopper. 3</li><li>Carefully remove the blister package from the Mix2Vial set by holding at the rim, and pulling vertically upwards. Make sure that you only pull away the blister package and not the Mix2Vial set. 4</li><li>Place the product vial on an even and firm surface. Invert the solvent vial with the Mix2Vial set attached and push the spike of the transparent adapter end straight down through the product vial stopper. The solvent will automatically flow into the product vial. 5</li><li>With one hand grasp the product-side of the Mix2Vial set and with the other hand grasp the solvent-side and unscrew the set carefully counterclockwise into two pieces to avoid excessive build-up of foam when dissolving the product. Discard the solvent vial with the blue Mix2Vial adapter attached. 6</li><li>Gently swirl the product vial with the transparent adapter attached until the substance is fully dissolved. Do not shake. 7</li><li>Draw air into an empty, sterile syringe. While the product vial is upright, connect the syringe to the Mix2Vial s Luer Lock fitting by screwing clockwise. Inject air into the product vial. Withdrawal and Application 8</li><li>While keeping the syringe plunger pressed, turn the system upside down and draw the solution into the syringe by pulling the plunger back slowly. 9</li><li>Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counterclockwise. Use the venipuncture kit supplied with the product, insert the needle into a vein. Let blood flow back to the end of the tube. Attach the syringe to the threaded, locking end of the venipuncture kit. The use of plastic disposable syringes is recommended as the ground glass surfaces of all-glass syringes tend to stick with solutions of this type. Inject/infuse the reconstituted solution slowly (at a rate not more than 6 ml per minute) into the vein following the instructions given to you by your doctor. Take care not to get any blood in the syringe containing the product. In case large volumes of Voncento are required, it is possible to pool several vials of Voncento together, via a commercially available infusion set (e.g. a syringe pump for giving medicines into a vein). However, in these cases the initially reconstituted solution of Voncento should not be diluted any further. Check yourself for any side effects that might happen straight away. If you have any side effects that might be related to the administration of Voncento, the injection or infusion should be stopped (see also section 2). If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</li></ol></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, Voncento can cause side effects, although not everybody gets them. Please contact your doctor immediately if:</p><p>you notice symptoms of allergic reactions In some cases it may progress to a serious allergic reaction (anaphylaxis) that causes severe difficulty in breathing, dizziness or shock. Allergic reactions may include the following symptoms: Swollen face, tongue, mouth or throat, difficulty in breathing and swallowing, hives, wheezing, burning and stinging where the infusion was given, chills, flushing, skin rash over the whole body, headache, fall in blood pressure, restlessness, faster heart beat, tightness of the chest (including chest pain and chest discomfort), back pain, tiredness (lethargy), nausea, vomiting, tingling.</p><p>you notice that the medicine stops working properly (bleeding is not stopped). For children not previously treated with factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients); however patients who have received previous treatment with factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients). If this happens your or your child s medicines may stop working properly and you or your child may experience persistent bleeding. You may develop an inhibitor (neutralising antibody) to VWF, in which case VWF will not work properly any more.</p><p>you notice any symptoms of an impaired perfusion in your extremities (e.g. cold and pale extremities) or vital organs (e.g. severe chest pain) There is a risk of formation of blood clots (thrombosis), particularly in patients with known risk factors (see also section 2). The following side effect has been observed very commonly (may affect more than 1 in 10 people):</p><p>Headache The following side effects have been observed commonly (may affect up to 1 in 10 people):</p><p>Increase in body temperature The following side effects have been observed uncommonly (may affect up to 1 in 100 people):</p><p>Taste alteration (dysgeusia)</p><p>Abnormal liver function test Side effects in children and adolescents Side effects in children and adolescents are expected to be the same as in adults. Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store voncento"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store voncento"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the label and carton.</p><p>Do not store above 25 C.</p><p>Do not freeze.</p><p>Voncento does not contain a preservative, so the reconstituted product should be used immediately.</p><p>If the reconstituted product is not administered immediately, storage times and conditions prior to use are the responsibility of the user.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Voncento contains The active substance is: 250 IU FVIII and 600 IU VWF per vial; after reconstitution with 5 ml of water for injection approx. 50 IU/ml FVIII and 120 IU/ml VWF. 500 IU FVIII and 1200 IU VWF per vial; after reconstitution with 10 ml of water for injection approx. 50 IU/ml FVIII and 120 IU/ml VWF. 500 IU FVIII and 1200 IU VWF per vial; after reconstitution with 5 ml of water for injection approx. 100 IU/ml FVIII and 240 IU/ml VWF. 1000 IU FVIII and 2400 IU VWF per vial; after reconstitution with 10 ml of water for injection approx. 100 IU/ml FVIII and 240 IU/ml VWF. See section The following information is intended for healthcare professionals only for further information. The other ingredients are: Calcium chloride, human albumin, sodium chloride, sodium citrate, sucrose, trometamol. See section 2 Voncento contains sodium . Solvent: Water for injections What Voncento looks like and contents of the pack Voncento is supplied as a white powder and solvent for solution for injection/infusion. The reconstituted solution should be clear to slightly opalescent, i.e. it might sparkle when held up to the light but must not contain any obvious particles. The immediate container of product and solvent vial consists of glass vial with a rubber stopper, plastic disc, and aluminium cap. Presentations One pack with 250 IU/600 IU or 500 IU/1200 IU containing:</p><ul><li><p>1 vial with powder</p></li><li><p>1 vial with 5 ml water for injections</p></li><li><p>1 filter transfer device 20/- One inner box containing: 1 disposable 10 ml syringe 1 venipuncture set 2 alcohol swabs 1 non-sterile plaster One pack with 500 IU/1200 IU or 1000 IU/2400 IU containing:</p></li><li><p>1 vial with powder</p></li><li><p>1 vial with 10 ml water for injections</p></li><li><p>1 filter transfer device 20/- One inner box containing: 1 disposable 10 ml syringe 1 venipuncture set 2 alcohol swabs 1 non-sterile plaster Not all pack sizes may be marketed. Marketing Authorization Holder and Manufacturer CSL Behring GmbH Emil-von-Behring-Stra e 35041 Marburg Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien CSL Behring NV T l/Tel: +32 15 28 89 Lietuva CentralPharma Communications UAB Tel: +370 5 243 0</p></li></ul><p>: +359 2 810 3Luxembourg/Luxemburg CSL Behring NV T l/Tel: +32 15 28 89 20 (BE) esk republika CSL Behring s.r.o. Tel: + 420 702 137 Magyarorsz g CSL Behring Kft. Tel.: +36 1 213 4Danmark CSL Behring AB Tel: +46 8 544 966 Malta AM Mangion Ltd. Tel: +356 2397 6Deutschland CSL Behring GmbH Tel: +49 69 30584Nederland CSL Behring BV Tel: + 31 85 111 96 Eesti CentralPharma Communications O<br/>Tel: +3726015Norge CSL Behring AB Tlf: +46 8 544 966<br/>CSL Behring<br/>: +30 210 7255 sterreich CSL Behring GmbH Tel: +43 1 80101 2Espa a CSL Behring S.A. Tel: +34 933 67 1Polska CSL Behring sp. z o.o. Tel: +48 22 213 22 France CSL Behring S.A. T l: + 33 (0)-1 53 58 54 Portugal CSL Behring Lda Tel: +351 21 782 62 Hrvatska PharmaSwiss d.o.o. Tel: +385 (1) 631-1Rom nia Prisum International Trading srl Tel: +40 21 322 0Ireland CSL Behring GmbH Tel: +49 69 30517Slovenija NEOX s.r.o.-podru nica v Sloveniji Tel:+ 386 41 42 0 sland CSL Behring AB S mi: +46 8 544 966 Slovensk republika CSL Behring s.r.o. Tel: +421 911 653 Italia CSL Behring S.p.A. Tel: +39 02 34964 Suomi/Finland CSL Behring AB Puh/Tel: +46 8 544 966<br/>CSL Behring<br/>: +30 210 7255 Sverige CSL Behring AB Tel: +46 8 544 966 Latvija CentralPharma Communications SIA Tel: +371 6 7450United Kingdom (Northern Ireland) CSL Behring GmbH Tel: +49 69 30517254 (DE) This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp6921fe94b12d3679a96f1d5a8683a92f"/>
<resource>
<MedicinalProductDefinition>
<id value="mp6921fe94b12d3679a96f1d5a8683a92f"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp6921fe94b12d3679a96f1d5a8683a92f"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp6921fe94b12d3679a96f1d5a8683a92f</b></p><a name="mp6921fe94b12d3679a96f1d5a8683a92f"> </a><a name="hcmp6921fe94b12d3679a96f1d5a8683a92f"> </a><a name="mp6921fe94b12d3679a96f1d5a8683a92f-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/857/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Voncento250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/857/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Voncento250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
